Chinese chemical inconsistency yields drug 'caveat emptor'

"Most Chinese chemicals are high quality, but poor oversight, weak regulation, and occasional grotesque negligence will likely compromise drug quality," says Roger Bate of the American Enterprise Institute. "There are no simple solutions to this problem; with healthcare costs escalating globally, the idea that we should pay even more for drugs to ensure safety is a tough sell. But at the very least, patients should realize that not all the drugs they take, even allegedly bioequivalent generics, will in fact work perfectly. It really is a case of caveat emptor." Story

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.